<VariationArchive VariationID="1322823" VariationName="NM_001429.4(EP300):c.2333dup (p.Asn779fs)" VariationType="Duplication" Accession="VCV001322823" Version="4" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-03-17" DateCreated="2021-11-29" MostRecentSubmission="2024-02-04">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1313120" VariationID="1322823">
      <GeneList>
        <Gene Symbol="EP300" FullName="E1A binding protein p300" GeneID="2033" HGNC_ID="HGNC:3373" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41092592" stop="41180077" display_start="41092592" display_stop="41180077" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41488613" stop="41576080" display_start="41488613" display_stop="41576080" Strand="+" />
          </Location>
          <OMIM>602700</OMIM>
          <Haploinsufficiency last_evaluated="2013-03-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=EP300">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2013-03-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=EP300">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_001429.4(EP300):c.2333dup (p.Asn779fs)</Name>
      <CanonicalSPDI>NC_000022.11:41149128:C:CC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>22q13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="41149128" stop="41149129" display_start="41149128" display_stop="41149129" variantLength="1" positionVCF="41149128" referenceAlleleVCF="A" alternateAlleleVCF="AC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="41545132" stop="41545133" display_start="41545132" display_stop="41545133" variantLength="1" positionVCF="41545132" referenceAlleleVCF="A" alternateAlleleVCF="AC" />
      </Location>
      <ProteinChange>N753fs</ProteinChange>
      <ProteinChange>N779fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.41545133dup" Assembly="GRCh37">
            <Expression>NC_000022.10:g.41545133dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.41149129dup" Assembly="GRCh38">
            <Expression>NC_000022.11:g.41149129dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009817.1" sequenceAccession="NG_009817" sequenceVersion="1" change="g.61520dup">
            <Expression>NG_009817.1:g.61520dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001362843.2" sequenceAccession="NM_001362843" sequenceVersion="2" change="c.2255dup">
            <Expression>NM_001362843.2:c.2255dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001349772.1" sequenceAccession="NP_001349772" sequenceVersion="1" change="p.Asn753fs">
            <Expression>NP_001349772.1:p.Asn753fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001429.4" sequenceAccession="NM_001429" sequenceVersion="4" change="c.2333dup" MANESelect="true">
            <Expression>NM_001429.4:c.2333dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001420.2" sequenceAccession="NP_001420" sequenceVersion="2" change="p.Asn779fs">
            <Expression>NP_001420.2:p.Asn779fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001429.3" sequenceAccession="NM_001429" sequenceVersion="3" change="c.2333dupC">
            <Expression>NM_001429.3:c.2333dupC</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1422" sequenceAccession="LRG_1422">
            <Expression>LRG_1422:g.61520dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1422t1" sequenceAccession="LRG_1422t1">
            <Expression>LRG_1422t1:c.2333dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1422p1" sequenceAccession="LRG_1422p1" change="p.Asn779fs">
            <Expression>LRG_1422p1:p.Asn779fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2145736063" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001429.4(EP300):c.2333dup (p.Asn779fs) AND not provided" Accession="RCV001783198" Version="4">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-09-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_001429.4(EP300):c.2333dup (p.Asn779fs) AND Rubinstein-Taybi syndrome due to EP300 haploinsufficiency" Accession="RCV002471160" Version="1">
        <ClassifiedConditionList TraitSetID="6729">
          <ClassifiedCondition DB="MedGen" ID="C3150941">Rubinstein-Taybi syndrome due to EP300 haploinsufficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-10-19" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2020-10-19" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2021-11-29" MostRecentSubmission="2024-02-04">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="6729" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15794" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Rubinstein-Taybi syndrome due to EP300 haploinsufficiency</ElementValue>
                <XRef ID="MONDO:0013364" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Rubinstein-Taybi syndrome 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">RSTS2</ElementValue>
                <XRef Type="MIM" ID="613684" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EP300</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17535" />
                <XRef ID="17535" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Rubinstein-Taybi syndrome (RSTS) is characterized by distinctive facial features, broad and often angulated thumbs and halluces, short stature, and moderate-to-severe intellectual disability. The characteristic craniofacial features are downslanted palpebral fissures, low-hanging columella, high palate, grimacing smile, and talon cusps. Prenatal growth is often normal, then height, weight, and head circumference percentiles rapidly drop in the first few months of life. Short stature is typical in adulthood. Obesity may develop in childhood or adolescence. Average IQ ranges between 35 and 50; however, developmental outcome varies considerably. Some individuals with EP300-RSTS have normal intellect. Additional features include ocular abnormalities, hearing loss, respiratory difficulties, congenital heart defects, renal abnormalities, cryptorchidism, feeding problems, recurrent infections, and severe constipation.</Attribute>
                <XRef ID="NBK1526" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301699</ID>
                <ID Source="BookShelf">NBK1526</ID>
              </Citation>
              <XRef ID="353284" DB="Orphanet" />
              <XRef ID="783" DB="Orphanet" />
              <XRef ID="C3150941" DB="MedGen" />
              <XRef ID="MONDO:0013364" DB="MONDO" />
              <XRef Type="MIM" ID="613684" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5414075" SubmissionDate="2022-12-21" DateLastUpdated="2022-12-24" DateCreated="2022-12-24">
        <ClinVarSubmissionID localKey="vcgs/unit_1/hg38_NM_001429_3_EP300_c_2333dupC" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002767754" DateUpdated="2022-12-24" DateCreated="2022-12-24" Type="SCV" Version="1" SubmitterName="Victorian Clinical Genetics Services, Murdoch Childrens Research Institute" OrgID="500104" OrganizationCategory="laboratory" OrgAbbreviation="VCGS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-10-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Based on the classification scheme VCGS_Germline_v1.3.3, this variant is classified as 5-Pathogenic. Following criteria are met: 0105 - The mechanism of disease for this gene is not clearly established. However, loss of function and dominant-negative have been suggested as possible mechanisms of disease and associated with Rubinstein-Taybi syndrome 2 (MIM#613684). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0701 - Other NMD-predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity (ClinVar; Decipher). (SP) 0807 - This variant has no previous evidence of pathogenicity. (I) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1204 - This variant has been shown to be de novo in the proband (parental status not tested but assumed) (VCGS #20G001924; #20G001925). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="EP300" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_4785</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001429.3:c.2333dupC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0013364" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_38</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3967676" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2021-11-29">
        <ClinVarSubmissionID localKey="b5f0c93c248a0ac9c5ae49fae4accdad42532bea7b78dc8914b00657ee1f84a7|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002022185" DateUpdated="2024-02-04" DateCreated="2021-11-29" Type="SCV" Version="3" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-09-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_001429.3:c.2333dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10694847</SubmissionName>
          <SubmissionName>SUB12926214</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5414075" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0013364" MappingRef="MONDO">
        <MedGen CUI="C3150941" Name="Rubinstein-Taybi syndrome due to EP300 haploinsufficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3967676" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

